168 results on '"Kaempf, Andy"'
Search Results
2. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.
3. An expanded universe of cancer targets
4. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
5. Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia
6. Impact of TP53 mutations in Triple Negative Breast Cancer
7. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia
8. Predicting stage progression in Binet stage A chronic lymphocytic leukemia
9. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
10. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells
11. Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy
12. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
13. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoidderived hematologic malignancies
14. Abstract A09: Targeting of FOXM1 recapitulates NPM1 mutations in chemo-sensitization of AML
15. Role of platelet count in a murine stasis model of deep vein thrombosis.
16. Functional genomic landscape of acute myeloid leukaemia
17. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia
18. Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
19. A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS)
20. Overall Survival in Myelofibrosis Treated with Allogeneic Hematopoietic Cell Transplant Is Impacted By Reversal of Marrow Fibrosis: A Single Institution Experience from Oregon Health and Science University
21. Pre-Transplant Measurable Residual Disease By Next-Generation Sequencing Is a Better Predictor of Relapse Compared to BCR-ABL PCR in Adult Patients with Ph+ Acute Lymphoblastic Leukemia
22. The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist
23. A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS)
24. Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study
25. Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy
26. Abstract A27: Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): A multicenter real-world evidence (RWE) study
27. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
28. Bacterial Infections Post-Allogeneic Transplant Are Associated with Higher Relapse Related Mortality
29. Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
30. FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy
31. Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study
32. Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry
33. Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia
34. Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML
35. Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia
36. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
37. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study
38. Abstract LT022: The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance
39. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
40. Evolution of Gilteritinib Resistance from Residual Disease to Relapse
41. Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate
42. 156 - Overall Survival in Myelofibrosis Treated with Allogeneic Hematopoietic Cell Transplant Is Impacted By Reversal of Marrow Fibrosis: A Single Institution Experience from Oregon Health and Science University
43. 151 - A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS)
44. 128 - Pre-Transplant Measurable Residual Disease By Next-Generation Sequencing Is a Better Predictor of Relapse Compared to BCR-ABL PCR in Adult Patients with Ph+ Acute Lymphoblastic Leukemia
45. An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)
46. Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia
47. Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia
48. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)
49. 450 - Bacterial Infections Post-Allogeneic Transplant Are Associated with Higher Relapse Related Mortality
50. Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.